ClinConnect ClinConnect Logo
Search / Trial NCT07129005

Radiomics-Based Non-Invasive MRI Differentiation of Uterine Sarcomas and Fibroids

Launched by TONGJI HOSPITAL · Aug 18, 2025

Trial Information

Current as of August 24, 2025

Enrolling by invitation

Keywords

Uterine Sarcoma Radiomics Multicenter Study Uterine Leiomyoma Magnetic Resonance Imaging (Mri) Machine Learning

ClinConnect Summary

Uterine fibroids are the most common benign gynecological tumors among women of reproductive age in China, with an incidence that has been increasing annually. Statistics show that the prevalence of uterine fibroids among women over 30 years old in China has reached 20%-30%, and the onset age is trending younger. During the "12th Five-Year Plan" period, significant progress was made in the minimally invasive and pharmacological treatment of uterine fibroids through enhanced allocation of medical resources, advancement of clinical research, and improvement of diagnostic and treatment guideli...

Gender

FEMALE

Eligibility criteria

  • Inclusion Criteria:
  • 1. Histopathological confirmation of uterine sarcoma or leiomyoma.
  • 2. Availability of preoperative MRI, includingT2WI and DWI, performed within 2 months of the surgery.
  • Exclusion Criteria:
  • 1. Tumors smaller than 2 cm. Small tumors may be difficult to accurately perform segmentation and feature extraction, which may affect the accuracy and reliability of the model.
  • 2. Non-primary uterine sarcomas. Sarcomas from other sites with metastasis to the uterus were excluded because the biological characteristics and imaging findings of these tumors may differ from those of primary uterine sarcomas and may lead to bias in the diagnostic model.
  • 3. Concurrent pelvic malignancies. To avoid the influence of other types of tumors on the imaging features of uterine sarcoma and leiomyoma, and to ensure the pertinence and accuracy of the model.

About Tongji Hospital

Tongji Hospital, affiliated with Tongji Medical College of Huazhong University of Science and Technology, is a leading medical institution in China dedicated to advancing healthcare through innovative research and clinical trials. With a robust infrastructure and a multidisciplinary team of experts, Tongji Hospital focuses on translating scientific discoveries into effective treatments and therapies. The hospital is committed to enhancing patient care by conducting rigorous clinical trials that adhere to the highest ethical and regulatory standards, fostering collaboration with both national and international research communities to drive medical advancements.

Locations

Wuhan, Hubei, China

Patients applied

0 patients applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported